Cold Agglutinin Disease: Symptoms, Diagnosis & Treatment

Cold agglutinin disease, or CAD, is a rare type of autoimmune hemolytic anemia ^7,9. This means the immune system helps destroy red blood cells too early ^7,9.

CAD can cause anemia, deep fatigue, and problems with blood flow after cold exposure ^2,5. Its effects can range from mild to severe ⁹.

This guide reviews warning signs, blood tests, treatment choices, and ways to limit cold triggers. A hematologist, or blood specialist, can tailor care to your needs.

CAD accounts for about 15% to 25% of autoimmune hemolytic anemia cases ^1,3,5. About one person per million receives this diagnosis each year ³.

CAD is tied to a small group of abnormal B cells in the bone marrow ^1,5. B cells are immune cells that make antibodies.

Cold agglutinin antibodies bind to red blood cells ^1,5. This antibody is most often immunoglobulin M, also called IgM ^3,5.

IgM antibodies can attach to red cells as blood cools near the skin ^1,3. The attached antibodies make red cells stick together, or agglutinate ^1,7.

This clumping can occur in the fingers, toes, ears, and nose ^3,5. These body parts are cooler than the center of the body ³.

Clumped cells can affect blood flow and change skin color. The cells may separate when blood returns to warmer areas ¹.

However, complement proteins can coat red blood cells ¹. These proteins mark the red cells for removal ¹.

IgM starts the classical complement pathway after binding to a red cell ^1,5. Complement is a group of proteins involved in immune defense.

A complement protein called C3b coats the affected cells ^1,3. Immune cells in the liver then remove many of them ^1,3.

This process is called extravascular hemolysis ^1,5. It means red cells are destroyed outside the blood vessels.

Most red cell loss in CAD occurs this way, mainly in the liver ^1,5. This helps explain why removing the spleen is often ineffective ⁵.

Complement activity can sometimes damage red cells inside blood vessels ^1,3. This process is called intravascular hemolysis.

Intravascular hemolysis can occur during an acute flare ⁵. Such flares may happen with fever or infection.

CAD is linked to a slow-growing B-cell disorder in the bone marrow ^1,5. This cell group makes the IgM antibody that drives CAD ⁵.

Cold agglutinin syndrome, or CAS, is a separate form of cold-related anemia ^1,5. CAS develops because of another disease or infection ^1,5.

Linked causes include *Mycoplasma pneumoniae*, Epstein-Barr virus, and aggressive lymphoma ¹. Some autoimmune diseases and blood cancers are also linked with secondary disease ⁹.

This difference matters when doctors choose a care plan. Treatment for CAS includes care for its underlying cause ⁵.

CAD also differs from warm autoimmune hemolytic anemia. Warm disease involves antibodies that react at normal body temperature.

The two disorders respond differently to treatment ^3,5. For example, steroids used in warm disease are not recommended for CAD ^3,5.

Symptoms can come from anemia, red cell loss, or poor blood flow ^2,5. The type and strength of symptoms can vary.

Anemia develops when too few healthy red blood cells remain ⁹. These cells carry oxygen to the body’s tissues ⁹.

Common anemia symptoms may include the following:

Fatigue can become a major part of the disease burden ⁵. It may affect daily tasks even when other signs seem mild.

Hemolysis means red blood cells break down earlier than expected ^7,9. This process can raise the amount of bilirubin in the blood ⁹.

Bilirubin is a yellow substance released during red cell breakdown ⁹. High levels can cause jaundice ⁹.

Possible signs of hemolysis can include these changes:

Dark urine may be absent when red cells are cleared outside blood vessels ⁴. Its absence does not rule out CAD.

Cold exposure can cause red cells to clump in cooler body areas ^1,3. These areas often include the fingers, toes, ears, and nose ^3,5.

Cold-related symptoms may include the following:

Acrocyanosis means blue or purple skin caused by reduced blood flow. It was the most common first symptom in one patient study ³.

These blood flow symptoms occur in CAD, which can also cause red cell clumping in cooled blood samples. Complement-blocking drugs may not improve them ⁵.

Symptoms may become worse during cold weather ^5,9. Fever can also trigger a sharp rise in red cell loss ⁵.

Some people need red blood cell transfusions during their illness ^5,6. About half were considered transfusion dependent for some period.

CAD is linked with a higher risk of blood clots ⁵. People with CAD may develop blood clots ⁵.

Finding cold antibodies does not prove that someone has CAD. Low cold-antibody levels alone do not establish anemia or red cell loss ³.

Doctors review symptoms, blood counts, and signs of hemolysis. They also test for antibodies and a bone marrow B-cell group.

Testing often starts with a complete blood count, also called a CBC ⁹. A CBC measures red cells, their size, and hemoglobin ⁹.

Hemoglobin is the protein that carries oxygen in red cells ⁹. A low level can support a diagnosis of anemia.

Other useful tests can include the following:

The marrow may release more young cells while replacing destroyed cells ⁹. Doctors consider these results together rather than using one result alone.

The direct antiglobulin test, or DAT, checks red cells for attached immune material ¹. It is also known as the direct Coombs test ⁴.

CAD causes a DAT result that is strongly positive for complement C3d ^1,3. IgG testing is usually negative ^1,5.

Weak IgG results can occur in up to 20% of cases ¹. A negative C3d result should lead doctors to consider another cause ³.

Warm autoimmune hemolytic anemia is one possible alternative ³. This distinction matters because treatment differs between warm and cold disease ³.

A titer shows how far serum can be diluted before clumping stops ⁴. A result of at least 1:64 at 4°C supports CAD ^3,5.

Cold antibodies can occur at levels below the threshold used to diagnose CAD ³. These antibodies are often present without hemolysis ³.

The titer does not show the antibody’s full effect ^1,3. Thermal amplitude may better predict whether the antibody will cause symptoms ^1,5.

Thermal amplitude is the highest temperature where the antibody reacts ^1,3. Antibodies reacting near body temperature are more likely to cause symptoms ³.

Cold antibodies can make red cells clump inside a blood sample ⁴. These clumps can distort automated blood count results ⁴.

The machine may report a falsely low red cell count ⁴. It may also report a very high average red cell size ⁴.

An unwarmed sample can give false red cell and hematocrit values ⁴. Hematocrit shows how much of the blood contains red cells.

The hemoglobin result is often still accurate ⁴. The testing machine measures it after breaking apart the red cells ⁴.

Tell laboratory staff about CAD before blood testing. This warning helps them watch for cold-related clumping.

Immunofixation can find small abnormal IgM proteins in the blood ⁴. This test can find proteins missed by standard protein testing ⁴.

Flow cytometry checks cell markers for an abnormal B-cell group ⁴. Doctors may use it on blood or bone marrow cells.

A bone marrow test can show clonal lymphoplasmacytic cells ⁴. Clonal means the cells came from the same original cell.

Doctors may also check for infection, lymphoma, or another disorder ^1,5. These findings can help separate CAD from secondary CAS ^1,5.

Treatment depends on symptoms and the effect of anemia. The care plan should reflect each person’s health and disease pattern.

Mild, stable disease may need cold avoidance and monitoring instead of medicine. Medicine is recommended when anemia causes symptoms ¹.

Disabling blood flow symptoms can also support starting treatment ¹. These symptoms may interfere with daily tasks and well-being ⁵.

Reasons to discuss medicine with a hematologist may include the following:

Avoiding cold can help manage mild disease. Extra care may also be needed during situations involving cold exposure.

Transfusions may support people with severe or ongoing anemia ^5,6. A blood specialist can help plan testing and transfusion care.

Transfused red cells lack the C3d coating found on many surviving patient cells ³. This leaves those cells open to complement-related damage ³.

Rituximab targets B cells involved in making the harmful antibody. About 45% to 60% of treated patients respond to rituximab alone ³.

Doctors may use rituximab alone for some people. Another drug may be added to improve the response.

Combination treatment can improve response rates ². However, it can also be harder to tolerate ².

Rituximab with bendamustine is one first-line choice, though it has been called investigational. Rituximab alone may fit other people better.

The choice depends on the person’s health and other traits. A hematologist should explain the likely benefits and harms.

Rituximab with fludarabine produced responses in up to 76% of patients ³. It also caused more side effects than rituximab alone ³.

Sutimlimab is an antibody that blocks the complement protein C1s ⁵. C1s helps drive the complement pathway involved in hemolysis ^1,5.

This drug targets complement rather than the B-cell group ⁵. These two treatment paths act on different parts of CAD ⁵.

Complement treatment may not improve cold-induced blood flow symptoms ⁵. Those symptoms come from red cell clumping, not complement activity ⁵.

A hematologist can compare this approach with B-cell treatment. Treatment needs can differ among patients.

Steroids are generally ineffective in CAD ^1,3,5. Experts advise against using them as standard CAD treatment ^1,3.

Splenectomy is surgery that removes the spleen. It is generally ineffective for CAD ⁵.

Most affected red cells are cleared in the liver rather than the spleen ^1,5. This helps explain the poor response to spleen removal ⁵.

Secondary CAS needs a different approach. Its treatment includes care for the infection, lymphoma, or other cause ⁵.

Daily planning can help reduce cold exposure. Mild disease may stay manageable with cold avoidance and careful planning.

These steps can support safer daily care:

Hemolysis can worsen during an acute flare ⁵. Ask your care team what to do if illness causes new changes.

Doctors may consider clot prevention during severe flares or near surgery ⁵. They must weigh clotting risk against bleeding risk.

Contact your care team if fatigue, weakness, jaundice, or dark urine is new or worse. These changes can occur with anemia or hemolysis ^7,9.

Tell your hematologist if cold-related pain or color changes limit daily life. Disabling blood flow symptoms may support starting drug treatment ¹.

Also report clear changes from your usual disease pattern. Your clinician can decide whether you need tests or a treatment review.

CAD involves IgM antibodies, red cell clumping, and complement-driven red cell loss ^1,5. It may cause anemia, fatigue, jaundice, and cold-related skin changes ^2,3,9.

Diagnosis uses hemolysis tests, C3d-positive DAT results, and cold antibody testing ^3,5. Bone marrow tests may also find the abnormal B-cell group ^4,5.

Treatment may include cold avoidance, transfusions, B-cell drugs, or complement treatment ^5,6. Steroids and spleen removal are generally not recommended ^3,5.

A hematologist can match treatment to your symptoms and health. Regular follow-up helps the team adjust care when your needs change.